Objective:To investigate the efficacy and safety of apatinib combined with etoposide capsules in the treatment of patients with platinum-resistant recurrent ovarian cancer.Methods:The clinical data and follow-up data of 63 patients with platinum-resistant recurrent ovarian cancer treated in Cancer Hospital of Jilin Province from January 2017 to June 2018 were analyzed retrospectively.According to the different treatment methods, the patients were divided into single group( n=28) and combination group( n=35). The patients in the single group were treated with etoposide capsules, while the patients in the combination group were treated with apatinib and etoposide capsules.The short-term clinical efficacy, progression free survival and adverse reactions of the two groups were compared. Results:The main adverse reactions of the two groups were anemia and leukopenia.There was no statistically significant difference in adverse reactions between the two groups( P>0.05). The objective response rate(ORR) of the combined group was 54.3%(19/35), which was higher than that of the single group [25.0%(7/28)](χ 2=5.504, P<0.05). The PFS of the combined group was 8 months(95% CI: 7.4-8.6 months), which was significantly longer than that of the single group(4 months, 95% CI: 3.5-4.5 months), the difference was statistically significant(χ 2=52.400, P<0.01). Conclusion:Apatinib combined with etoposide capsules is effective in the treatment of platinum resistant recurrent ovarian cancer, which can significantly extend the median PFS, without increasing the incidence of serious adverse reactions.